Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152138 | 0.93 | GPR119 (0.33) | GPR119KCNH2SIGMAR1HCRTR2NR1H2 | |
| SCHEMBL148491 | 0.88 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL149799 | 0.85 | GPR119 (0.42) | GPR119KCNH2SIGMAR1MCHR1 | |
| SCHEMBL149935 | 0.85 | MCHR1 (0.41) | GPR119KCNH2MCHR1 | |
| SCHEMBL149751 | 0.84 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL148869 | 0.83 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL152099 | 0.82 | GPR119 (0.43) | GPR119KCNH2 | |
| SCHEMBL151876 | 0.82 | GPR119 (0.35) | GPR119KCNH2 | |
| SCHEMBL121289 | 0.81 | MCHR1 (0.44) | GPR119KCNH2MCHR1 | |
| SCHEMBL149302 | 0.81 | GPR119 (0.39) | GPR119KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | claimed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885KCNH2 2010/4885SIGMAR1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.